Browsing by Author "Inderbir Singh"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Assessment of Suspending Properties of Katira Gum: Formulation and Evaluation of Nimesulide Suspension
    (Chitkara University Publications, 2013-11) Inderbir Singh; Amrinder Singh; Garima Thakur; Oluwatoyin A. Odeku
    There are several hydrophilic polymers that have been employed as suspending agents in pharmaceutical suspensions due to their ability to form colloidal gel in aqueous medium. In the present study, katira gum obtained from the bark of Cochlospermum religiosum has been evaluated as suspending agent in nimesulide suspension and compared with acacia gum at concentration of 1-5%. Sedimentation volume, rheology, particle size, degree of flocculation and in-vitro drug release were employed as assessment parameters. The result showed that at all concentrations, katira gum higher suspending capability compared acacia gum. The sedimentation volume was found to increase from 0.36 to 1 (A1-A3) and 0.26 to 0.56 (B1-B3). The viscosity of suspensions (A1 and A2) containing gum katira as suspending agent was found to be 1.35 and 2.4 centipoise and 0.63- 1.05 centipoise (B1- B3). Plots between shear stress and rate of shear were plotted using different concentrations indicates the obedience to newtonian behaviour. Degree of flocculation of gum katira and gum acacia suspension was established to be 1.69 and 1.05 respectively.
  • No Thumbnail Available
    Item
    Exploring RP-HPLC Method for analysis of Axitinib in Bulk and in-house Tablets
    (Chitkara University Publications, 2018-11-02) Shailesh S Chalikwar; Satish D Kayande; Inderbir Singh; Atul A Shirkhedkar
    Axitinib is a tyrosine kinase Inhibiter. In a commenced analysis, a effortless and responsive high-performance liquid-chromatography method was developed and validated for the quantitative estimation of Axitinib in bulk and in-house tablet dosage form. The present method was developed and validated using LC-GC Qualisil BDS C18 (250 mm × 4.6 mm, 5 μm). The separation of Axitinib was employed using a methanol: water 85:15% v/vas a mobile phase at optimal flow rate 1 mL/min and column oven temperature 30°C. While, Axitinib was examined at 330 nm with a photo diode array detector; retention timewas found to be 3.23 min.The intended method was validated by ICH rules for the accuracy, precision, sensitivity, and ruggedness. The linearity was followed in the concentration range of 4 – 24 μg/ mL as demonstrated by correlation coefficient (r2) of 0.9994. The robustness of proposed method was assessed by purposelyvarying the chromatographic conditions. Consequently, the intended method can routinely be subjected for th estimation of Axitinib in bulk and in tablets formulation.
  • No Thumbnail Available
    Item
    Exploring the Patent Landscape and Regulatory Prospective on Pharmaceutical Cocrystals
    (Chitkara University Publications, 2023-04-15) Ritu Rathi; Yukta Guggal; Twinkle; Varneet Sandhu; Inderbir Singh
    Background: Cocrystals are not new, they have sparked considerable interest among scientists and the pharmaceutical business in the last decade. Cocrystals are multiphase formations composed of at least two particles that are held together by noncovalent bonds. Cocrystal offers unmatched physio-engineered attributes (like stability, melting point, taste concealment, dissolvability, purity, bioavailability, etc.) without changing the pharmacological capabilities of the drug. Recently, as pharmaceutical cocrystal development has increased, we have given more attention to the absurd state of cocrystals. Purpose: The purpose of the current review is to explore the patent perspective on pharmaceutical cocrystals. And to discuss the new regulations that came up from the U.S. Food and Drug Administration (USFDA) and European Medicines Agency (EMA). Methods: In order to accomplish the said objectives, literature was surveyed from GOOGLE PATENTS, GOOGLE SCHOLAR, PUBMED, EBSCO, etc. type for search engines for a detailed overview of the patentability and regulatory status of pharmaceutical cocrystals. Conclusions: The journey of pharmaceutical cocrystals is bit challenging and still going on. In addition, if attention is drawn on some challenging aspects such as scalability, reproducibility, herbal bioactives cocrystals and 3D printed cocrystals related preparation and stability challenges, it can prove to be a paradigm shift in drug discovery processes.